DUBLIN–(BUSINESS WIRE)–“An Essential Overview of the Pharmaceutical and Biotech Industries Training Course (Mar 12, 2026)” has been added to ResearchAndMarkets.com’s offering. The pharmaceutical and biotechnology industries are both complex and developing at a rapid pace. This intensive one-day course will give you an invaluable overview, refresher and update on all the important aspects from discovery … [Read more…]

— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. … [Read more…]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2033” report has been added to ResearchAndMarkets.com’s offering. The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 … [Read more…]

CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models Favorable safety and pharmacodynamics demonstrated in non-human primates TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–#Crispr–Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published … [Read more…]

High-Performance, High-Accuracy Storage Server Solution Earns Government Recognition TAIPEI, Taiwan–(BUSINESS WIRE)–#datamanagement–Phison Electronics (8299TT), a leading provider of NAND controllers and NAND storage solutions, today (December 24, 2025) announced its participation in the inaugural International FHIR Server Performance Competition hosted by Taiwan’s Ministry of Health and Welfare (MOHW). Leveraging its self-developed, on-premises high-performance storage server solution, … [Read more…]

TORONTO–(BUSINESS WIRE)–Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus: Nutraceuticals – Innovations through the Company’s Quicksome™ technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture – … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “X-Ray Inspection System Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering. Market research reveals the X-Ray Inspection System Market is poised for significant growth, projected to increase from USD 1.63 billion in 2024 to USD 2.59 billion by 2032 at a CAGR of 5.96%. As quality control and safety standards … [Read more…]

– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR … [Read more…]